ArticleFrontiers in public health2017
C-Reactive Protein Correlates with Negative Symptoms in Patients with Schizophrenia.
Article in Frontiers in public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05105542 (Muscarinic M1 Receptor Availability and Cognition in Schizophrenia), which is not on this map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Muscarinic M1 Receptor Availability and Cognition in Schizophrenia
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials.Molecular psychiatry · 2026Pooled it
- Association Between Inflammatory Markers and Cognitive Function in Adults With Bipolar Disorder: A Systematic Review.Acta psychiatrica Scandinavica · 2026Pooled it
- Schizophrenia is associated with altered DNA methylation variance.Molecular psychiatry · 2025Pooled it
- Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentary.Brain, behavior, and immunity · 2023Pooled it
- The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.Molecular psychiatry · 2022Pooled it
- Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.European archives of psychiatry and clinical neuroscience · 2022Trial
- Inflammation and sarcopenia exhibit distinct associations with psychopathology and executive function in schizophrenia.Journal of the Chinese Medical Association : JCMA · 2026Article
- Mitochondrial control of blood-brain barrier homeostasis in neuroinflammatory psychiatric disorders.Frontiers in molecular neuroscience · 2026Review
- Linking Metabolic Disorders and Immune System Phenomena in Schizophrenia: The Role of Adipose Tissue and Inflammation.Biomedicines · 2025Review
- Relationship Between Family Support, C-Reactive Protein and Body Mass Index Among Outpatients with Schizophrenia.Healthcare (Basel, Switzerland) · 2025Article
- Inflammatory markers and cognitive deficits in first-episode psychoses - A cross-sectional study.Indian journal of psychiatry · 2025Article
- The association of SOD and HsCRP with the efficacy of sulforaphane in schizophrenia patients with residual negative symptoms.European archives of psychiatry and clinical neuroscience · 2024Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- Review
- A Comparison of the Relationship Between C-Reactive Protein Levels and Cognitive Functions in Patients with Schizophrenia, First-Episode Psychosis, and Healthy Controls.Psychiatry and clinical psychopharmacology · 2022Article
- Evidence of genetic overlap and causal relationships between blood-based biochemical traits and human cortical anatomy.Translational psychiatry · 2022Article
- Associations between inflammatory marker profiles and neurocognitive functioning in people with schizophrenia and non-psychiatric comparison subjects.Journal of psychiatric research · 2022Article
- Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease.International journal of molecular sciences · 2021Review
- Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort.Journal of psychiatric research · 2021Article
- Serum level of high sensitive C-reactive protein and IL - 6 markers in patients with treatment-resistant schizophrenia in Ethiopia: a comparative study.BMC psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral and CNS-localized inflammatory processes are hypothesized to contribute to the complex pathophysiology of schizophrenia. Elevated levels of the acute phase reactant C-reactive protein (CRP) have been observed in schizophrenia, yet relatively few studies have investigated the association between this inflammatory biomarker and psychotic symptoms in schizophrenia. This study is a pilot cross-sectional analysis investigating the relation of plasma CRP levels and the positive and negative symptoms of schizophrenia (the primary aim), assessed by the Positive and Negative Syndrome Scale (PANSS). A secondary analysis was also performed evaluating the potential association of CRP with cognitive function using the NIH Toolbox Cognitive Test Battery. After adjusting for age, sex, race, and body mass index, a positive correlation was observed between CRP and PANSS negative symptoms (rho = 0.37,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.